Article citationsMore>>

Rizvi, N.A., Cho, B.C., Reinmuth, N., Lee, K.H., Luft, A., Ahn, M.J., van den Heuvel, M.M., Cobo, M., Vicente, D., Smolin, A., Moiseyenko, V., Antonia, S.J., Le Moulec, S., Robinet, G., Natale, R., Schneider, J., Shephard, F.A., Geater, S.L., Garon, E.B., Kim, E.S., Goldberg, S.B., Nakagawa, K., Raja, R., Higgs, B.W., Boothman, A.M., Zhao, L., Scheurig, U., Stockman, P.K., Chand, V.K. and Peters, S. (2020) Durvalumab with or without Tremelimumab vs Standard Chemotherapy in First-Line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial. Journal of the American Medical Association Oncology, 6, 661-674.
https://doi.org/10.1001/jamaoncol.2020.0237

has been cited by the following article:

Follow SCIRP
Twitter Facebook Linkedin Weibo
Contact us
+1 323-425-8868
customer@scirp.org
WhatsApp +86 18163351462(WhatsApp)
Click here to send a message to me 1655362766
Paper Publishing WeChat
Free SCIRP Newsletters
Copyright © 2006-2024 Scientific Research Publishing Inc. All Rights Reserved.
Top